MarketPulse
A

$APGE

4 articles found
4 positive
0 negative
0 neutral
The Motley FoolThe Motley Fool··Jonathan Ponciano

Apogee CEO Sells $1.5M in Stock Despite 100% Surge; Clinical Data Tells Real Story

Apogee Therapeutics CEO sells $1.5M in shares via pre-planned program amid stock's 100% surge, but bullish clinical data and $350M capitalization warrant investor focus.
APGEbiotechclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Apogee Therapeutics Raises $350M via Public Offering to Fuel Biotech Pipeline

Apogee Therapeutics prices $350M offering at $70/share to fund development of inflammatory disease treatments, with lead candidate Zumilokibart targeting atopic dermatitis.
APGEclinical-stagepublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Apogee Therapeutics to Unveil 52-Week Phase 2 Data for APG777 Atopic Dermatitis Treatment

Apogee Therapeutics to present 52-week Phase 2 data for APG777 in atopic dermatitis on March 23, 2026, signaling major clinical development milestone.
APGEbiologicsatopic dermatitis
The Motley FoolThe Motley Fool··Jonathan Ponciano

Great Point Partners Doubles Down on Apogee Therapeutics With $28M Position

Great Point Partners expands Apogee Therapeutics stake to $28.23M, now its largest holding. Stock doubled in value; Phase 2 atopic dermatitis data expected mid-2026.
APGEbiotechclinical trials